Suppressing APOE4-induced neural pathologies by targeting the VHL–HIF axis
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2417515122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Wei I Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158. Hauptthemen laut MEDLINE: Von Hippel-Lindau Tumor Suppressor Protein, Apolipoprotein E4, Caenorhabditis elegans Proteins, Hypoxia-Inducible Factor 1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of General Medical Sciences (NIGMS), NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
The ε4 variant of human apolipoprotein E ( APOE4 ) is a key genetic risk factor for neurodegeneration in Alzheimer’s disease and elevated all-cause mortality in humans. Understanding the factors and mechanisms that can mitigate the harmful effects of APOE4 has significant implications. In this study, we find that inactivating the VHL-1 (Von Hippel–Lindau) protein can suppress mortality, neural and behavioral pathologies caused by transgenic human APOE4 in Caenorhabditis elegans . The protective effects of VHL-1 deletion are recapitulated by stabilized HIF-1 (hypoxia-inducible factor), a transcription factor degraded by VHL-1. HIF-1 activates a genetic program that safeguards against mitochondrial dysfunction, oxidative stress, proteostasis imbalance, and endolysosomal rupture—critical cellular events linked to neural pathologies and mortality. Furthermore, genetic inhibition of Vhl reduces cerebral vascular injury and synaptic lesions in APOE4 mice, suggesting an evolutionarily conserved mechanism. Thus, we identify the VHL–HIF axis as a potent modulator of APOE4 -induced neural pathologies and propose that targeting this pathway in nonproliferative tissues may curb cellular damage, protect against neurodegeneration, and reduce tissue injuries and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158.
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
- Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
- HHMI, Chevy Chase, MD 20815.
- Department of Neurology, University of California San Francisco, San Francisco, CA 94158.
- Department of Neuroscience, The Center for Learning and Memory, Waggoner Center for Alcohol and Addiction Research, Institute of Neuroscience, University of Texas at Austin, Austin, TX 78712.
ORCID-Profile: Wei I Jiang, Yichun Ji, Dengke K Ma
Förderung
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- NIH HHS
- NIA NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- NHGRI NIH HHS
Zitieren
APA
Jiang, W. I., Cao, Y., Xue, Y., Ji, Y., Winer, B. Y., Chandra, R., Zhang, X. F., Zhang, M., Singhal, N. S., Pierce, J. T., Chen, S., & Ma, D. K. (2025). Suppressing APOE4-induced neural pathologies by targeting the VHL–HIF axis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2417515122
Vancouver
Jiang WI, Cao Y, Xue Y, Ji Y, Winer BY, Chandra R, et al. Suppressing APOE4-induced neural pathologies by targeting the VHL–HIF axis. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2417515122
BibTeX
@article{Jiang2025,
author = {Jiang, Wei I and Cao, Yiming and Xue, Yue and Ji, Yichun and Winer, Benjamin Y and Chandra, Rashmi and Zhang, Xingyuan Fischer and Zhang, Mengqi and Singhal, Neel S and Pierce, Jonathan T and Chen, Song and Ma, Dengke K},
title = {Suppressing APOE4-induced neural pathologies by targeting the VHL–HIF axis},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2417515122}
}
EUVIMED